×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Clovis Oncology Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag
Yahoo Lifestyle Canada
Clovis Oncology ( NASDAQ:CLVS ) Third Quarter 2022 Results Key Financial Results Revenue: US$30.7m (down 19% from 3Q...
4 days ago
FDA sends CRL to Clovis in last-gasp bid for Rubraca nod
Fierce Pharma
Six months after filing for bankruptcy, Clovis Oncology was hoping for a last gasp win for fading cancer drug Rubraca.
11 months ago
Rubraca sheds positive light for PARP inhibitors in endometrial cancer
Clinical Trials Arena
On 18 March 2024, positive Phase II results of Clovis Oncology's Rubraca were presented at the Society of Gynecologic Oncology conference,...
1 month ago
Clovis Gets EU Acceptance for Rubraca Label Expansion Filing
Yahoo News Singapore
Clovis Oncology's (CLVS) regulatory application seeking label expansion of Rubraca as maintenance treatment was accepted for review in...
2 weeks ago
EC approves pharmaand’s Rubraca as advanced ovarian cancer maintenance treatment
PMLiVE
The European Commission (EC) has approved pharmaand's (pharma&) Rubraca (rucaparib) as a first-line maintenance treatment for advanced...
6 months ago
Small-Cell Lung Cancer Market to Accelerate Substantially During the Study Period (2019-2032), Assesses ...
PR Newswire
PRNewswire/ -- DelveInsight's Small-Cell Lung Cancer Market Insights report includes a comprehensive understanding of current treatment...
7 months ago
Embattled Clovis Oncology Files for Chapt. 11, Sells Radioligand Therapeutic to Novartis
BioSpace
Embattled Clovis Oncology Files for Chapt. 11, Sells Radioligand Therapeutic to Novartis ... Clovis Oncology filed for Chapter 11 bankruptcy and...
17 months ago
Clovis finally throws in the towel, files for bankruptcy
Fierce Pharma
Clovis Oncology finally throws in the towel, files for bankruptcy ... The writing has been on the wall for months, and, now, Clovis Oncology has...
17 months ago
Novartis pays $40M cash for biotech's radiopharmaceutical tech
Fierce Biotech
Novartis is offering up to $425M in biobucks for exclusive licensing rights to 3B Pharmaceuticals' FAP-targeting peptide tech.
13 months ago
Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286
Business Wire
Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286 ... BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology,...
17 months ago